Successful treatment of IgG4-related disease with tocilizumab monotherapy

Autoimmun Rev. 2023 Apr;22(4):103296. doi: 10.1016/j.autrev.2023.103296. Epub 2023 Feb 11.

Authors

Mitsuhiro Akiyama¹, Yutaro Hayashi², Koji Suzuki², Tsutomu Takeuchi², Yuko Kaneko²

Affiliations

¹ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 1608582 Tokyo, Japan; Department of Rheumatology, Japanese Red Cross Ashikaga Hospital, Ashikaga, Japan. Electronic address: mitsuaki@keio.jp.
² Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 1608582 Tokyo, Japan.

PMID: 36781039
DOI: 10.1016/j.autrev.2023.103296

No abstract available

Keywords: IgG4-related disease; Interleukin-6; Tocilizumab.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Antirheumatic Agents*
Humans
Immunoglobulin G4-Related Disease* / drug therapy
Treatment Outcome

Substances

tocilizumab
Antibodies, Monoclonal, Humanized
Antirheumatic Agents